Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
CellTrans Inc. · Type 1 Diabetes Mellitus
Phase 3
Active, not recruiting
21
2026-04
Industry sponsor intelligence
CellTrans Inc.Clinical Pipeline.
Lead-sponsor view of CellTrans Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 1
- Recruiting
- 0
- Active
- 1
- Completed
- 0
- Results posted
- 1
- Avg enrollment
- 21
Pipeline overview
Programs by phase and activity.
Velocity
CellTrans Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
1phase labels
Early Phase 10
Phase 10
Phase 20
Phase 31
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Exenatide → | 1 | 0 | 0 | 1 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
No studies in this snapshot.
Search sponsor records
All CellTrans Inc. studies.
This page groups studies where CellTrans Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
1 matching study
Last registry update first
Recent updates